C. Yan Cheng is a senior scientist at the Population Council’s Center for Biomedical Research, affiliated with the Council's Reproductive Health program. His research focuses on developing new male contraceptive methods and gaining a better understanding of male fertility and infertility.
Cheng’s laboratory has pioneered research on adjudin, a drug that causes male infertility by interrupting spermatogenesis. Adjudin has proven safe, effective, and reversible in animal models and is moving toward human trials.
Cheng serves as editor-in-chief of the peer-reviewed journal Spermatogenesis and is an ad-hoc reviewer of grant proposals submitted to the National Institutes of Health’s Cellular, Molecular and Integrative Reproduction Study Section. Cheng is also a member of the Endocrine Society and the American Physiological Society. He holds five US patents.
In 1997, Cheng received the Best Scientific Paper Award from the American Society of Andrology; he was also awarded the Richard E. Weizman Memorial Award from the Endocrine Society in 1988. He joined the Population Council in 1981 as a postdoctoral trainee. He holds a PhD in biochemistry and cell biology from the University of Newcastle, New South Wales, Australia and an undergraduate degree from the Chinese University of Hong Kong.